TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03242707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue injection
Description: 20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Synvisc-One® is a high molecular weight sodium hyaluronate.
Study: NCT01561573

Intervention type: DEVICE
Group type: OTHER
Intervention: Point of care ultrasound
Description: A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
Study: NCT02047474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study: NCT01145872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Study: NCT02974270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Study: NCT02047474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03539302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide Acetate
Description: Oral inhalation form using a nebulizer
Study: NCT01480323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion, 3 mg/kg, day 2, 23, 44, 65
Study: NCT04722432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outside the Scope (OTS), Detachable Catheter System
Description: Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study
Study: NCT01769248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration
Description: Fine needle aspiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration
Description: Fine needle aspiration
Study: NCT03408327

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable technology
Description: Fitness wristband \& APP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable technology
Description: Fitness wristband \& APP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINE group
Description: Promote social interaction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group activities
Description: Which was developed by applying social cognitive theory

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion manual
Description: Which was about general physical activity promotion content
Study: NCT02758509

Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a + Ribavirin

Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a + Ribavirin + Boceprevir

Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a + Ribavirin +Telaprevir

Intervention type: DRUG
Intervention: Ledipasvir/Sofosbuvir

Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir+Dasabuvir

Intervention type: DRUG
Intervention: Daclatasvir+Sofosbuvir

Intervention type: DRUG
Intervention: Simeprevir+Sofosbuvir
Study: NCT01769248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle biopsy
Description: FNB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle biopsy
Description: FNB
Study: NCT05067413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanterior obturator nerve gateway approach
Description: Distal rectal transection of cases in the experimental group will be performed using transanterior obturator nerve gateway approach

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Total mesorectal excision approach
Description: Distal rectal transection of cases in the control group will be performed using total mesorectal excision approach
Study: NCT02035371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose will be administered subcutaneously (s.c. under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: A single dose will be administered subcutaneously (s.c. under the skin)
Study: NCT04413513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Attention Training Program (IATP)
Description: Integrated attention training program (IATP) is a newly developed cognitive training programs that combined relaxation technique with integrated attentional training into daily life activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: Health educational sessions on health concerns and physical diseases commonly found in old age
Study: NCT00480636

Intervention type: DRUG
Intervention: Fragmin (dalteparin sodium )
Description: Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
Study: NCT01646697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo cytopathologic sample collection
Study: NCT00326911

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
Study: NCT00843739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMST - Active Treatment
Description: Hand held device used for strengthening expiratory muscles

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham EMST
Description: Four week sham device training program
Study: NCT00326911

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: I.V.infusions of 250 mg/m2 (over 60 minutes) weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
Study: NCT04605575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib 320mg + Vinorelbine
Description: pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
Study: NCT02922920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Description: 16 fl. oz of tart cherry juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 16 fl. oz of placebo
Study: NCT00758524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching Placebo
Description: LCI699-matching placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching Placebo
Description: LCI699-matching placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching Placebo
Description: LCI699-matching placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching Placebo
Description: LCI699-matching placebo oral capsules
Study: NCT04605575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib 400mg + Vinorelbine
Description: pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus Vinorelbine
Description: pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
Study: NCT02530294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium Topical Wipes
Description: Topical wipes containing glycopyrronium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle (placebo) topical wipes
Study: NCT04027218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry heat
Description: The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High pressure
Description: It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination of dry heat and high pressure
Description: The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
Study: NCT04509440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic dextrose 5% in water (D5W) solution
Description: Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )
Description: Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
Study: NCT01753453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240mcg/kg, solution, subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 10 mcg/kg, solution, subcutaneous injection
Study: NCT00517868

Intervention type: DRUG
Group type: OTHER
Intervention: URG101
Description: Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.

Intervention type: DRUG
Group type: OTHER
Intervention: URG101
Description: Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Liquid formulation without active URG101 drug components

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Liquid formulation without active URG101 drug components
Study: NCT02559778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceritinib
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceritinib
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vorinostat
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vorinostat
Description: One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFMO
Description: DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
Study: NCT03323359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Common Surgical Techniques
Description: Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
Study: NCT03300804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20-herb formulation
Description: Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo herb formulation
Study: NCT02592070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants will walk on the treadmill for 30 minutes at a moderate intensity.
Study: NCT02413710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy protein containing foods
Description: Daily consumption of 2 food products, each providing 15g of soy protein per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Guidance
Description: Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
Study: NCT04342130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 30 mg oral tablet
Study: NCT00003452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00661791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage therapy without exercise
Description: Infants will receive massage twice a day; 15 minutes each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage therapy with exercise
Description: Infants will receive massage with exercise twice a day; 15 minutes each.
Study: NCT03029104

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CXLO Corneal Strengthening Solution and UVA Illumination Device
Description: CXLO Corneal Strengthening Solution

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CXLO Corneal Strengthening Solution and UVA Illumination Device
Description: CXLO Corneal Strengthening Solution
Study: NCT01753453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 10 mcg/kg, solution, subcutaneous injection
Study: NCT02177266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the study drug.
Study: NCT03595371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapansutrile
Description: 500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
Study: NCT02904811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing for Ct infection immediately
Description: Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing for Ct infection at the end of the study
Description: Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
Study: NCT02424240

Intervention type: OTHER
Intervention: IGF-1/IGFBP-3 ratio
Description: IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 \& IGFBP-3 combination
Study: NCT00115596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formal Curriculum; Low-Fidelity Simulation
Description: The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
Study: NCT00846924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a 30-day ambulatory cardiac event monitor
Description: Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour Holter
Description: Repeat standard 24-hour Holter Monitor
Study: NCT01403207

Intervention type: OTHER
Intervention: musculoskeletal
Description: Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.